Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.

Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O'Rourke M, Brenckman W, Tilton R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E.

Clin Colorectal Cancer. 2011 Jun;10(2):85-96. doi: 10.1016/j.clcc.2011.03.003. Epub 2011 Apr 22.

PMID:
21859559
2.

A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906.

Tilton R, Paiva AA, Guan JQ, Marathe R, Jiang Z, van Eyndhoven W, Bjoraker J, Prusoff Z, Wang H, Liu SH, Cheng YC.

Chin Med. 2010 Aug 20;5:30. doi: 10.1186/1749-8546-5-30.

3.

The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.

Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH, Cheng YC.

Sci Transl Med. 2010 Aug 18;2(45):45ra59. doi: 10.1126/scitranslmed.3001270.

4.

Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).

Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, Jiang Z, Ye M, Chu E, Cheng YC.

J Chromatogr A. 2010 Sep 10;1217(37):5785-93. doi: 10.1016/j.chroma.2010.07.045. Epub 2010 Jul 21.

5.

IRF5 is required for late-phase TNF secretion by human dendritic cells.

Krausgruber T, Saliba D, Ryzhakov G, Lanfrancotti A, Blazek K, Udalova IA.

Blood. 2010 Jun 3;115(22):4421-30. doi: 10.1182/blood-2010-01-263020. Epub 2010 Mar 17.

6.

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.

Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC.

Phytomedicine. 2010 Mar;17(3-4):161-9. doi: 10.1016/j.phymed.2009.12.016. Epub 2010 Jan 22.

PMID:
20092990
7.

Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.

Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Jiang Z, Su T, Cheng YC.

Anticancer Res. 2009 Oct;29(10):4083-92.

8.

Evidence from the Cochrane Collaboration for Traditional Chinese Medicine therapies.

Manheimer E, Wieland S, Kimbrough E, Cheng K, Berman BM.

J Altern Complement Med. 2009 Sep;15(9):1001-14. doi: 10.1089/acm.2008.0414. Review.

9.

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, MonsurrĂ³ V, Buller RM, Stroncek DF, Wang E, Szalay AA, Marincola FM.

BMC Genomics. 2009 Jul 7;10:301. doi: 10.1186/1471-2164-10-301.

10.

NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis.

Pandey AK, Yang Y, Jiang Z, Fortune SM, Coulombe F, Behr MA, Fitzgerald KA, Sassetti CM, Kelliher MA.

PLoS Pathog. 2009 Jul;5(7):e1000500. doi: 10.1371/journal.ppat.1000500. Epub 2009 Jul 3.

11.

Analysis of gene expression data using BRB-ArrayTools.

Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y.

Cancer Inform. 2007 Feb 4;3:11-7.

12.

Bioactivity-guided identification and cell signaling technology to delineate the immunomodulatory effects of Panax ginseng on human promonocytic U937 cells.

Lee DC, Yang CL, Chik SC, Li JC, Rong JH, Chan GC, Lau AS.

J Transl Med. 2009 May 14;7:34. doi: 10.1186/1479-5876-7-34.

13.

Cytochrome c/cardiolipin relations in mitochondria: a kiss of death.

Kagan VE, Bayir HA, Belikova NA, Kapralov O, Tyurina YY, Tyurin VA, Jiang J, Stoyanovsky DA, Wipf P, Kochanek PM, Greenberger JS, Pitt B, Shvedova AA, Borisenko G.

Free Radic Biol Med. 2009 Jun 1;46(11):1439-53. doi: 10.1016/j.freeradbiomed.2009.03.004. Epub 2009 Mar 12. Review.

14.

Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs.

Lee JH, Chun T, Park SY, Rho SB.

Biochim Biophys Acta. 2008 Sep;1783(9):1654-62. doi: 10.1016/j.bbamcr.2008.04.006. Epub 2008 Apr 22.

15.

The immunologic constant of rejection.

Wang E, Worschech A, Marincola FM.

Trends Immunol. 2008 Jun;29(6):256-62. doi: 10.1016/j.it.2008.03.002. Epub 2008 May 3. Review.

PMID:
18457994
16.

The IRF family transcription factors in immunity and oncogenesis.

Tamura T, Yanai H, Savitsky D, Taniguchi T.

Annu Rev Immunol. 2008;26:535-84. doi: 10.1146/annurev.immunol.26.021607.090400. Review.

PMID:
18303999
17.

Immunological aspects of cancer chemotherapy.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G.

Nat Rev Immunol. 2008 Jan;8(1):59-73. Review.

PMID:
18097448
18.

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G, Zitvogel L.

Immunol Rev. 2007 Dec;220:47-59. Review.

PMID:
17979839
19.

High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.

Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd.

J Immunother. 2007 Sep;30(6):596-606.

PMID:
17667523
20.

From traditional Chinese medicine to rational cancer therapy.

Efferth T, Li PC, Konkimalla VS, Kaina B.

Trends Mol Med. 2007 Aug;13(8):353-61. Epub 2007 Jul 17. Review.

PMID:
17644431

Supplemental Content

Support Center